US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Cingulate Inc.
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
SCTL
Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023
From
Cingulate Inc.
Via
GlobeNewswire
Tickers
CING
CINGW
